Get started
Author

Thomas M. Lancaster

Observed names: Thomas Lancaster, Thomas M Lancaster
ORCID: 0000-0003-2357-6531
Observed ORCID: 0000-0003-2357-6531
OpenAlex ID: A5101854705
Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
2021 · David G. Alleva, Andrea R. Delpero, et al. · Vaccine · 39
Ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in dogs
2022 · Sean E. Hulsebosch, Jully Pires, et al. · Journal of Veterinary Internal Medicine · 28
A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452
2023 · Eline A. Feitsma, Yester F. Janssen, et al. · Vaccine · 16
Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
2022 · Yester F. Janssen, Eline A. Feitsma, et al. · Vaccine · 16
PDF
An ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in cats
2021 · Chen Gilor, Sean E. Hulsebosch, et al. · Journal of Veterinary Internal Medicine · 14
PDF
Planar cell polarity pathway and development of the human visual cortex
2018 · Jean Shin, Shaojie Ma, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 4
PDF
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine
2024 · David G. Alleva, Eline A. Feitsma, et al. · npj Vaccines · 2
PDF
Abstract P1-21-05: A novel long-acting insulin for cancer therapy reduces xenograft tumor growth
2020 · Lynsey M Fettig, Xihong Zhang, et al. · Cancer Research · 1
Abstract P4-02-01: Targeting insulin receptor in estrogen receptor positive breast cancer
2022 · Jingran Cao, Lynsey M. Fettig, et al. · Cancer Research
Works count: 9
Citation count: 120
H-index: 5
I10-index: 5
Year
Topic
Type